Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes

Launched by WUHAN UNION HOSPITAL, CHINA · Nov 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called Denosumab in treating osteoporosis, a condition that weakens bones, and its impact on sarcopenia, which is the loss of muscle mass and strength. The trial involves randomly assigning participants to receive either Denosumab or a placebo (a dummy treatment) for one year. Researchers will then compare the results to see how well Denosumab works in improving bone health and muscle strength in people with osteoporosis and sarcopenia.

To be eligible for this trial, participants must be diagnosed with postmenopausal or age-related osteoporosis and also have sarcopenia. They should not have taken any other osteoporosis medications before joining the study. Participants can expect regular check-ups during the year to monitor their health and assess any changes. This trial aims to find a better treatment option for individuals facing both osteoporosis and sarcopenia, helping improve their overall quality of life. If you or someone you know has these conditions and is interested, it’s worth discussing with a healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of postmenopausal/senile osteoporosis after examination and assessment.
• • Clinical diagnosis of postmenopausal/senile osteoporosis combined with sarcopenia after examination and assessment.
• • Have not previously taken any other anti-osteoporosis drugs.
• Exclusion Criteria:
• • Clinical diagnosis of pathological fractures.
• • Have participated in another clinical trial within the past 3 months or have taken other anti-osteoporosis drugs within the past 6 months.
• • Severe chronic metabolic diseases or serious organ failure.